Muhammad Akbar Ramadhan Munandar, et al. “Cost-Effectiveness of Pembrolizumab As First-Line Treatment for PD-L1 Positive NSCLC: A Systematic Review”. The International Journal of Medical Science and Health Research, vol. 23, no. 2, Jan. 2026, pp. 64-130, https://doi.org/10.70070/h3zdy035.